EGFR and neoplasm: Moreover, compared to the LCO group, CAF-targeting treatment did not significantly enhance the sensitivity of EGFR-mutated LC23 tumor cells in LCAs to osimertinib (Fig. 6k, l, Supplementary Fig. 8g), further suggesting little protection of LC23 CAFs for the corresponding tumor cells.